Analyst Price Targets — SABS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 6:01 am | Michael Yee | UBS | $7.00 | $3.62 | StreetInsider | UBS Starts SAB Biotherapeutics (SABS) at Buy |
| September 17, 2025 10:58 am | — | Leerink Partners | $7.00 | $2.58 | TheFly | SAB Biotherapeutics initiated with an Outperform at Leerink |
| June 7, 2024 3:45 am | Kumaraguru Raja | Loop Capital Markets | $8.00 | $2.84 | StreetInsider | Brookline Capital Markets Starts SAB Biotherapeutics (SABS) at Buy |
| April 2, 2024 6:44 am | Edward White | H.C. Wainwright | $6.00 | $4.29 | StreetInsider | SAB Biotherapeutics (SABS) PT Lowered to $6 at H.C. Wainwright following Q4 report |
| August 11, 2022 7:41 am | — | Chardan Capital | $3.00 | $1.12 | Benzinga | Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $3 |
Latest News for SABS
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases,…
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in March: Leerink Partners Global Healthcare Conference Date:…
SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation
Viking Therapeutics (NASDAQ: VKTX - Get Free Report) and SAB Biotherapeutics (NASDAQ: SABS - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of current
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SABS.
U.S. House Trading
No House trades found for SABS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.